Related Experiment Video
Updated: Jan 30, 2026

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays
Published on: November 29, 2014
The lysine-specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
Theodoros Rampias1, Dimitris Karagiannis1, Margaritis Avgeris2
1Biomedical Research Foundation Academy of Athens, Athens, Greece.
Abstract:
Genome-wide studies in tumor cells have indicated that chromatin-modifying proteins are commonly mutated in human cancers. The lysine-specific methyltransferase 2C (KMT2C/MLL3) is a putative tumor suppressor in several epithelia and in myeloid cells. Here, we show that downregulation of KMT2C in bladder cancer cells leads to extensive changes in the epigenetic status and the expression of DNA damage response and DNA repair genes. More specifically, cells with low KMT2C activity are deficient in homologous recombination-mediated double-strand break DNA repair. Consequently, these cells suffer from substantially higher endogenous DNA damage and genomic instability. Finally, these cells seem to rely heavily on PARP1/2 for DNA repair, and treatment with the PARP1/2 inhibitor olaparib leads to synthetic lethality, suggesting that cancer cells with low KMT2C expression are attractive targets for therapies with PARP1/2 inhibitors.
Insights
Low lysine-specific methyltransferase 2C (KMT2C) expression in bladder cancer impairs DNA repair, increasing genomic instability. This suggests KMT2C-deficient tumors are vulnerable to PARP1/2 inhibitors like olaparib.
Area of Science:
- Oncology
- Epigenetics
- DNA Repair
Background:
- Chromatin-modifying proteins are frequently mutated in human cancers.
- Lysine-specific methyltransferase 2C (KMT2C/MLL3) is implicated as a tumor suppressor in various cell types.
Purpose of the Study:
- To investigate the role of KMT2C in bladder cancer.
- To determine the impact of KMT2C downregulation on DNA damage response and repair pathways.
- To explore therapeutic vulnerabilities in KMT2C-deficient bladder cancer.
Main Methods:
- Analysis of KMT2C expression and its effects on epigenetic status in bladder cancer cells.
- Assessment of DNA damage response and repair gene expression.
- Evaluation of homologous recombination deficiency and sensitivity to PARP1/2 inhibition.
Main Results:
- Downregulation of KMT2C in bladder cancer cells alters epigenetic profiles and DNA repair gene expression.
- Cells with low KMT2C activity exhibit homologous recombination deficiency and increased endogenous DNA damage.
- Genomic instability is significantly higher in KMT2C-low bladder cancer cells.
Conclusions:
- KMT2C deficiency compromises DNA repair, leading to genomic instability in bladder cancer.
- Bladder cancer cells with low KMT2C expression are hypersensitive to PARP1/2 inhibitors.
- Targeting KMT2C-deficient bladder cancers with PARP1/2 inhibitors like olaparib presents a promising therapeutic strategy.
More Related Videos
Related Concept Videos
Overview of DNA Repair
Chemically...
Overview of DNA Repair
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Mismatch Repair
Base-pairing and DNA Repair
Nucleotide Excision Repair

